hVIVO PLC (AIM:HVO) has picked up more than £5 million in fresh contracts at its German business, giving the clinical research group a firmer footing as it heads towards next year.
The London-listed company, best known for running “human challenge” studies where volunteers are exposed to viruses in tightly controlled settings, said its CRS subsidiary had signed five early-stage trial deals since September.
Two of those came from returning German pharmaceutical customers, which the group said showed the strength of CRS’s long-standing relationships in the country.
The work will feed into hVIVO’s sales pipeline for 2026, with most of the revenue booked next year. The studies are set to begin later this year and in the first half of 2026.
Trials will run at CRS sites in Mannheim and Kiel, covering a broad mix of treatment areas including heart and metabolic disease, skin conditions, infectious disease, kidney impairment and cancer.
The company said CRS’s experience across these fields widens the range of projects the group can compete for. Venn Life Sciences, another part of the business, will provide biometry services, essentially the statistical design and analysis of trials, showing how hVIVO is trying to cross-sell more work within the group.
CRS has run more than 1,800 studies to date, helping drug developers with everything from designing their early trials and finding volunteers to managing day-to-day operations and final close-out.
Volunteer recruitment, often a bottleneck in early-stage research, has been bolstered by hVIVO’s own management system, which the group says has made the process more efficient.
Dr Yamin “Mo” Khan, hVIVO’s chief executive, said: “Securing over £5 million in new contracts, including two mid-sized pharma clients, underscores our strong reputation and the strategic importance of CRS within the group.
"These wins demonstrate the success of our integration strategy and the value we deliver through combined expertise across the hVIVO Group.
"CRS has seen an increased conversion rate of proposals to contracts year-to-date versus 2024 and with a robust sales pipeline and continued efficiency improvements,
"CRS remains on track to become earnings accretive in 2026.”
The shares rose 3% to 6.09p
Broker Cavendish, which has a 16.5p price target, told investors: "We maintain our forecasts and remind investors that, given the combination of hVIVO’s human challenge trials capabilities and full-service early phase CRO offering, we consider the business to be well-positioned as a leading partner for early-phase clinical research."
Peel Hunt, which values the stock at 10p, added that "these contracts now reaffirm CRS’ strong reputation in Germany".
---UPDATES TO ADD BROKER COMMENTS---